BRPI0215045B1 - método analítico para detectar esfingomielinase alcalina e kit para uso em tal método - Google Patents
método analítico para detectar esfingomielinase alcalina e kit para uso em tal método Download PDFInfo
- Publication number
- BRPI0215045B1 BRPI0215045B1 BRPI0215045A BR0215045A BRPI0215045B1 BR PI0215045 B1 BRPI0215045 B1 BR PI0215045B1 BR PI0215045 A BRPI0215045 A BR PI0215045A BR 0215045 A BR0215045 A BR 0215045A BR PI0215045 B1 BRPI0215045 B1 BR PI0215045B1
- Authority
- BR
- Brazil
- Prior art keywords
- sample
- sphingomyelinase
- alkaline
- buffer containing
- fluorescence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 102100036093 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Human genes 0.000 title claims abstract description 9
- 101000876377 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Proteins 0.000 title claims abstract description 9
- 238000004458 analytical method Methods 0.000 title abstract description 6
- 239000003550 marker Substances 0.000 claims abstract description 5
- 239000000523 sample Substances 0.000 claims description 21
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 12
- 239000013060 biological fluid Substances 0.000 claims description 12
- 210000003608 fece Anatomy 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 9
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 9
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012131 assay buffer Substances 0.000 claims description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 108010000659 Choline oxidase Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- 239000003833 bile salt Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 6
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 210000000941 bile Anatomy 0.000 claims description 5
- 239000011539 homogenization buffer Substances 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000011535 reaction buffer Substances 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 229940093761 bile salts Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229950004354 phosphorylcholine Drugs 0.000 claims description 4
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 238000002731 protein assay Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 2
- 239000012888 bovine serum Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- BQVYCHTZPMKIJX-UHFFFAOYSA-N trimethyl-[2-(1h-phosphol-2-yloxy)ethyl]azanium Chemical compound C[N+](C)(C)CCOC1=CC=CP1 BQVYCHTZPMKIJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- -1 resorufin compound Chemical class 0.000 claims 1
- 239000013595 supernatant sample Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 2
- 101710124951 Phospholipase C Proteins 0.000 description 35
- 101710166827 Sphingomyelinase Proteins 0.000 description 35
- 101710122751 Sphingomyelinase C Proteins 0.000 description 35
- 230000000694 effects Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 5
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20011100A IE20011100A1 (en) | 2001-12-21 | 2001-12-21 | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
| PCT/IT2002/000811 WO2003056031A2 (en) | 2001-12-21 | 2002-12-19 | Method and kit for detecting alkaline sphingomyelinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR0215045A BR0215045A (pt) | 2004-11-03 |
| BRPI0215045B1 true BRPI0215045B1 (pt) | 2015-09-29 |
Family
ID=11042874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0215045A BRPI0215045B1 (pt) | 2001-12-21 | 2002-12-19 | método analítico para detectar esfingomielinase alcalina e kit para uso em tal método |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20050118152A1 (enExample) |
| EP (1) | EP1456405B1 (enExample) |
| JP (2) | JP2005512601A (enExample) |
| KR (1) | KR101002068B1 (enExample) |
| CN (1) | CN101126716A (enExample) |
| AR (1) | AR038037A1 (enExample) |
| AT (1) | ATE408707T1 (enExample) |
| AU (1) | AU2002367123B2 (enExample) |
| BR (1) | BRPI0215045B1 (enExample) |
| CA (1) | CA2469796C (enExample) |
| CY (1) | CY1108512T1 (enExample) |
| DE (1) | DE60228993D1 (enExample) |
| DK (1) | DK1456405T3 (enExample) |
| EG (1) | EG25804A (enExample) |
| ES (1) | ES2312666T3 (enExample) |
| HR (1) | HRP20040632B1 (enExample) |
| HU (1) | HU228812B1 (enExample) |
| IE (1) | IE20011100A1 (enExample) |
| IL (2) | IL162513A0 (enExample) |
| MX (1) | MXPA04005919A (enExample) |
| NO (1) | NO331806B1 (enExample) |
| NZ (1) | NZ533806A (enExample) |
| PL (1) | PL207876B1 (enExample) |
| PT (1) | PT1456405E (enExample) |
| RU (1) | RU2316002C2 (enExample) |
| SI (1) | SI1456405T1 (enExample) |
| WO (1) | WO2003056031A2 (enExample) |
| ZA (1) | ZA200405762B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20011100A1 (en) | 2001-12-21 | 2003-07-09 | Vsl Pharma Ltd | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
| PL1973561T3 (pl) * | 2005-12-15 | 2011-08-31 | Elanco Us Inc | Enzymy do zmniejszania stresu immunologicznego |
| CN103760348B (zh) * | 2014-02-11 | 2015-03-11 | 苏州博源医疗科技有限公司 | 一种甘胆酸免疫检测试剂及其制备和检测方法 |
| CN104614371A (zh) * | 2015-02-15 | 2015-05-13 | 史春龙 | 一种在便器中检测排泄物生化指标的方法及使用该方法的检测设备 |
| CN116106281A (zh) * | 2023-02-03 | 2023-05-12 | 大连医科大学 | 一种粪便样本中肠道菌脂肪酶活性的检测方法 |
| CN117630364B (zh) * | 2023-12-05 | 2024-07-30 | 临沂大学 | 一种双酶型免疫荧光系统检测痕量黄曲霉毒素b1的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1311495B1 (it) * | 1999-06-09 | 2002-03-13 | Mendes S U R L | Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento. |
| US6265179B1 (en) * | 2000-02-01 | 2001-07-24 | Molecular Probes, Inc. | Detection of phosphate using coupled enzymatic reactions |
| IE20011100A1 (en) | 2001-12-21 | 2003-07-09 | Vsl Pharma Ltd | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
-
2001
- 2001-12-21 IE IE20011100A patent/IE20011100A1/en not_active IP Right Cessation
-
2002
- 2002-12-19 DE DE60228993T patent/DE60228993D1/de not_active Expired - Lifetime
- 2002-12-19 RU RU2004122426/15A patent/RU2316002C2/ru not_active IP Right Cessation
- 2002-12-19 AT AT02805875T patent/ATE408707T1/de active
- 2002-12-19 EP EP02805875A patent/EP1456405B1/en not_active Expired - Lifetime
- 2002-12-19 HU HU0402542A patent/HU228812B1/hu not_active IP Right Cessation
- 2002-12-19 IL IL16251302A patent/IL162513A0/xx unknown
- 2002-12-19 AU AU2002367123A patent/AU2002367123B2/en not_active Ceased
- 2002-12-19 DK DK02805875T patent/DK1456405T3/da active
- 2002-12-19 PT PT2805875T patent/PT1456405E/pt unknown
- 2002-12-19 BR BRPI0215045A patent/BRPI0215045B1/pt not_active IP Right Cessation
- 2002-12-19 CN CNA200710147169XA patent/CN101126716A/zh active Pending
- 2002-12-19 WO PCT/IT2002/000811 patent/WO2003056031A2/en not_active Ceased
- 2002-12-19 KR KR1020047008886A patent/KR101002068B1/ko not_active Expired - Fee Related
- 2002-12-19 NZ NZ533806A patent/NZ533806A/en not_active IP Right Cessation
- 2002-12-19 MX MXPA04005919A patent/MXPA04005919A/es active IP Right Grant
- 2002-12-19 AR ARP020104993A patent/AR038037A1/es active IP Right Grant
- 2002-12-19 SI SI200230740T patent/SI1456405T1/sl unknown
- 2002-12-19 CA CA2469796A patent/CA2469796C/en not_active Expired - Fee Related
- 2002-12-19 ES ES02805875T patent/ES2312666T3/es not_active Expired - Lifetime
- 2002-12-19 US US10/499,336 patent/US20050118152A1/en not_active Abandoned
- 2002-12-19 HR HRP20040632AA patent/HRP20040632B1/hr not_active IP Right Cessation
- 2002-12-19 JP JP2003556548A patent/JP2005512601A/ja active Pending
- 2002-12-19 PL PL374085A patent/PL207876B1/pl unknown
- 2002-12-21 EG EG2002121379A patent/EG25804A/xx active
-
2004
- 2004-06-14 IL IL162513A patent/IL162513A/en not_active IP Right Cessation
- 2004-07-13 NO NO20042992A patent/NO331806B1/no not_active IP Right Cessation
- 2004-07-20 ZA ZA200405762A patent/ZA200405762B/en unknown
-
2006
- 2006-02-23 US US11/359,619 patent/US7211410B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/712,417 patent/US7323317B2/en not_active Expired - Fee Related
-
2008
- 2008-11-13 CY CY20081101308T patent/CY1108512T1/el unknown
-
2009
- 2009-04-22 JP JP2009104135A patent/JP5009332B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5009332B2 (ja) | アルカリ性スフィンゴミエリナーゼを検出するための分析方法およびかかる方法に使用するキット | |
| CN113645846B (zh) | 检测胃肠道疾病的组合物和方法 | |
| JP2009195239A6 (ja) | アルカリ性スフィンゴミエリナーゼを検出するための分析方法およびかかる方法に使用するキット | |
| CA2722444C (en) | Acetaminophen assay | |
| CN100491540C (zh) | 用于检测碱性鞘磷脂酶的试剂盒 | |
| JP6989872B2 (ja) | 先天性代謝異常症６疾患の同時スクリーニング検査法 | |
| JP6989871B2 (ja) | 乾燥血液ろ紙を用いた低ホスファターゼ症のマススクリーニング検査法 | |
| ES2232124T3 (es) | Metodo de medida del indice de resorcion osea. | |
| HK1117906A (en) | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method | |
| HK1075069B (en) | Kit for detecting alkaline sphingomyelinase | |
| JP6320441B2 (ja) | ライソゾーム病２疾患責任酵素の迅速マススクリーニング検査法 | |
| Ongun | Nutritional follow-up in patients with ischemic stroke: With a screening test or with blood parameters? | |
| van Dael et al. | Partial hypoxanthine–guanine phosphoribosyl transferase deficiency without elevated urinary hypoxanthine excretion | |
| Manual | Free Fatty Acid Assay Kit (Colorimetric) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |